Accepted Manuscript Title : Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic / pharmacodynamic modelling and Monte Carlo simulation

[1]  Liang’an Chen,et al.  Multicentre investigation of pathogenic bacteria and antibiotic resistance genes in Chinese patients with acute exacerbation of chronic obstructive pulmonary disease , 2015, The Journal of international medical research.

[2]  A. Thomson,et al.  Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations. , 2015, The Journal of antimicrobial chemotherapy.

[3]  S. Shi,et al.  Tolerability and Pharmacokinetics of Biapenem Following Single and Multiple Intravenous Administrations in Healthy Chinese Subjects: An Open-Label, Randomized, Single-Center Study , 2013, Drug Research.

[4]  S. Zhai,et al.  Pharmacokinetics and Pharmacodynamics of Meropenem in Elderly Chinese with Lower Respiratory Tract Infections , 2011, Drugs & aging.

[5]  H. Derendorf,et al.  Clinical Pharmacokinetics of Meropenem and Biapenem in Bile and Dosing Considerations for Biliary Tract Infections Based on Site-Specific Pharmacodynamic Target Attainment , 2011, Antimicrobial Agents and Chemotherapy.

[6]  Libo Zhao,et al.  Improved RP-HPLC method to determine biapenem in human plasma/urine and its application to a pharmacokinetic study , 2011, Arzneimittelforschung.

[7]  C. Gomersall,et al.  Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region. , 2011, International journal of antimicrobial agents.

[8]  Andrew C. Hooker,et al.  Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models , 2011, The AAPS Journal.

[9]  Ming Xia,et al.  The stability of biapenem and structural identification of impurities in aqueous solution. , 2009, Journal of pharmaceutical and biomedical analysis.

[10]  Y. Nasuhara,et al.  Comparison of the Pharmacodynamics of Biapenem in Bronchial Epithelial Lining Fluid in Healthy Volunteers Given Half-Hour and Three-Hour Intravenous Infusions , 2009, Antimicrobial Agents and Chemotherapy.

[11]  H. Ohge,et al.  Pharmacodynamic evaluation of biapenem in peritoneal fluid using population pharmacokinetic modelling and Monte Carlo simulation. , 2008, International journal of antimicrobial agents.

[12]  H. Ohge,et al.  Pharmacokinetic-Pharmacodynamic Target Attainment Analysis of Biapenem in Adult Patients: A Dosing Strategy , 2008, Chemotherapy.

[13]  S. Nishimura,et al.  Population pharmacokinetics and pharmacodynamics of biapenem in paediatric patients , 2008, Journal of clinical pharmacy and therapeutics.

[14]  Jerome J. Schentag,et al.  Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. , 2008, International journal of antimicrobial agents.

[15]  D. Nicolau,et al.  Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. , 2007, Diagnostic microbiology and infectious disease.

[16]  M. Itoh,et al.  Pharmacokinetic study of pleural fluid penetration of carbapenem antibiotic agents in chemical pleurisy. , 2006, Respiratory medicine.

[17]  O. Cars,et al.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. , 2005, The Journal of antimicrobial chemotherapy.

[18]  R. Ariano,et al.  Pharmacokinetics and Pharmacodynamics of Meropenem in Febrile Neutropenic Patients with Bacteremia , 2005, The Annals of pharmacotherapy.

[19]  G. Drusano,et al.  Integration of Population Pharmacokinetics, a Pharmacodynamic Target, and Microbiologic Surveillance Data to Generate a Rational Empiric Dosing Strategy for Cefepime against Pseudomonas aeruginosa , 2003, Pharmacotherapy.

[20]  G L Drusano,et al.  Prevention of resistance: a goal for dose selection for antimicrobial agents. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  M. Karlsson,et al.  Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis , 2002, AAPS PharmSci.

[22]  G. Drusano,et al.  Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC Breakpoint , 2001, Antimicrobial Agents and Chemotherapy.

[23]  M. Nakashima,et al.  Phase 1 study of L-627, biapenem, a new parenteral carbapenem antibiotic. , 1993, International journal of clinical pharmacology, therapy, and toxicology.

[24]  K. Nishiki,et al.  Renal dehydropeptidase-I stability of LJC 10,627, a new carbapenem antibiotic , 1992, Antimicrobial Agents and Chemotherapy.

[25]  P. Kiratisin,et al.  Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region. , 2013, International journal of antimicrobial agents.

[26]  J. Karlowsky,et al.  Comparative Review of the Carbapenems , 2012, Drugs.

[27]  Y. Tanigawara,et al.  Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic–pharmacodynamic analysis , 2011, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[28]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .

[29]  K. Bush,et al.  Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases. , 1995, The Journal of antimicrobial chemotherapy.

[30]  T. Miura,et al.  Pharmacokinetic study of biapenem. , 1994 .

[31]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .